Final version of 2009 AJCC melanoma staging and classification - sprookjes - yvandenbroek - TriplyDB

Final version of 2009 AJCC melanoma staging and classification

Final version of 2009 AJCC melanoma staging and classification

http://www.wikidata.org/entity/Q29614803

about

Time course and pattern of metastasis of cutaneous melanoma differ between men and women A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma Tests to assist in the diagnosis of cutaneous melanoma in adults: a generic protocol Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma Systemic treatments for metastatic cutaneous melanoma Sentinel lymph node biopsy followed by lymph node dissection for early cutaneous melanoma Interferon alpha for the adjuvant treatment of cutaneous melanoma Interferon alpha for the adjuvant treatment of cutaneous melanoma Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy Improved survival with vemurafenib in melanoma with BRAF V600E mutation Arginine deprivation therapy for malignant melanoma Melanoma immunotherapy dominates the field State of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now Clinical utilities and biological characteristics of melanoma sentinel lymph nodes Advances in immunotherapy for melanoma Somatic DNA mutation analysis in targeted therapy of solid tumours Guidelines of the Brazilian Dermatology Society for diagnosis, treatment and follow up of primary cutaneous melanoma--Part I Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications Tailoring the Treatment of Melanoma: Implications for Personalized Medicine Pembrolizumab: First in Class for Treatment of Metastatic Melanoma Update in genetic susceptibility in melanoma New developments in the management of advanced melanoma - role of pembrolizumab Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets The clinical features and optimal treatment of anorectal malignant melanoma To what extent are current guidelines for cutaneous melanoma follow up based on scientific evidence?Update and Review on the Surgical Management of Primary Cutaneous Melanoma Safety and outcome of treatment of metastatic melanoma using 3-bromopyruvate: a concise literature review and case study Melanoma: new insights and new therapies Optimal management of metastatic melanoma: current strategies and future directions New diagnostic aids for melanoma Progression of cutaneous melanoma: implications for treatment A Global Review of Melanoma Follow-up Guidelines The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy Circulating serologic and molecular biomarkers in malignant melanoma Melanoma: from mutations to medicine Melanoma cells break down LPA to establish local gradients that drive chemotactic dispersal Uveal melanoma cells utilize a novel route for transendothelial migration Methyl sulfone induces loss of metastatic properties and reemergence of normal phenotypes in a metastatic cloudman S-91 (M3) murine melanoma cell line

P2860

Q21134734-8C2EB3D1-725E-4F9D-869D-D166C403E16F Q21245488-9C1B4851-23B5-4A2D-9FF4-3367D920AE94 Q24186719-62FE0F7E-A4D2-48F2-94FA-B581479FC45B Q24187945-F5425C5B-2E8D-4411-9841-30AAE48BCE03 Q24194804-BCFF81AD-41B0-40E4-AD8E-30BD8B74F540 Q24201860-B4CAA05B-29A7-48D7-AF5A-8058AE5D33C7 Q24201908-D8C1C608-66F9-426C-BA42-6FCEC9C10D30 Q24235257-FBB6EB28-DBED-491A-B0E6-D9A23F6B7D21 Q24596055-7289B338-83D8-4762-AF99-DDE2E7C936FE Q24631953-64E153F5-9BD6-404F-8D64-82ED9D565A42 Q24634269-301883EE-74B5-47A9-B193-F4AAA2D66CA3 Q26738671-424B9F45-FDD7-4683-83FF-588541749E2C Q26745557-14242243-06E8-4096-9B02-81241918F8A2 Q26747723-C989D0EA-97D0-4601-ABA5-2BB636DD5A79 Q26768558-913E5F09-E541-4E14-A749-BA8F504A3772 Q26770324-38A61790-534D-4951-B2D3-E824E786E4FB Q26770468-B9F5938E-9355-46E3-A7E2-3C245B783EC6 Q26770492-A5194428-8F20-4400-B5DE-B0E01C595B0C Q26775546-363E01BA-C841-44A4-96C7-35355840975F Q26775806-9CE52389-2FC3-471D-9B8A-C56BDB1169FA Q26777886-23C38F48-EA76-443C-9151-634A4451A8FD Q26778756-33DCC469-B776-456D-8E0E-85B9F077ABA1 Q26781931-7B8C580E-E3BF-429A-96AC-6BFFA7699F7C Q26782222-BB7E1461-1338-4A78-BD9E-61A6DA985A2D Q26795735-844704DD-D704-4C0E-80EB-08F7CF48D501 Q26828599-7BF5A16D-BEAE-4001-A214-0064B1BB379E Q26828637-6769DE8C-CB47-4542-AA6C-563BF20465FB Q26851966-1F9963C5-888F-4A40-BA88-B390BEB372E6 Q26852150-DB969BA0-01F2-4D8D-BC1F-9F280CB9C562 Q26853127-9E9CEB76-2B8D-4C22-BFA9-0C679790FA5D Q26997338-F965EB44-5744-45CD-8BD0-4E80E51FCFBE Q27000654-15278954-8B93-47CD-8AF6-F3B1892B6877 Q27001734-E2F5BA1E-AB18-4082-98B9-7F248B476A6F Q27004541-40E0402B-4830-4078-A24F-D05DD0DFF390 Q27004672-6C7CF6EB-664B-495A-A6BC-2C849FF5AA83 Q27020946-9E55FDC3-A56B-4B07-943E-AFD87DE100D5 Q27024061-F4F3348B-FEC0-41D0-B8F1-7E61DBA9E524 Q27313853-A18B92D3-5885-42E5-9456-D3A465C0F378 Q27319660-BA6EFE64-7D3B-459B-A235-E34754E58CFD Q27322879-F9C9FCA7-5A90-4636-AC5F-1817E6EA7755

P2860

Final version of 2009 AJCC melanoma staging and classification

http://www.wikidata.org/entity/Q29614803

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Final version of 2009 AJCC melanoma staging and classification

@ast

Final version of 2009 AJCC melanoma staging and classification

@en

type

label

Final version of 2009 AJCC melanoma staging and classification

@ast

Final version of 2009 AJCC melanoma staging and classification

@en

prefLabel

Final version of 2009 AJCC melanoma staging and classification

@ast

Final version of 2009 AJCC melanoma staging and classification

@en

P1433

Q29614803-D3CB9F78-17DD-4C65-B69B-1937AFBC91DB

P1476

Q29614803-EF66A01B-457E-4588-9845-E3E6E1F93083

P2093

Q29614803-0120280B-156B-46F9-901C-5C9C71A779FC

Q29614803-0C5CE90F-6DB9-4884-94F3-B4695C79C1C9

Q29614803-14578CEC-892F-4D7A-A6EB-1C3FFDBA360A

Q29614803-1843312D-8733-4740-B9D2-8295DB685029

Q29614803-1E1437E4-8F15-4A41-947D-8F091D2C6C95

Q29614803-2359F5F7-CBC1-4137-A222-4615AAC61B7A

Q29614803-2A3418CE-FE38-47D0-B6EA-D03F80E97BC7

Q29614803-2DED4790-EF38-44B7-93D9-BAEADC0205DF

Q29614803-3EBDF811-F91E-4D11-9C76-95228846AC05

Q29614803-426DA2AB-77F0-4AA2-B555-06D8A3412CB1

P2860

Q29614803-014A9E4B-F592-47B0-B748-2BF1BF39AC30

Q29614803-2F4AF959-12B5-47F2-B188-68C28BE0B811

Q29614803-36D5B5A8-70D1-46A3-B950-8925D7E431C5

Q29614803-3EBFC3D4-A71D-46EB-B75F-0D8D0A61ADD0

Q29614803-42EBDDDD-067E-4C10-8E1E-7BCA0715F185

Q29614803-4876A914-65F1-417C-B39C-E1ACDA3B94D8

Q29614803-49117AA1-76BC-491F-947A-F1294091C96C

Q29614803-4A333855-D055-4A58-BAB6-F8DC969EFC9D

Q29614803-4BA95523-E4DF-4D50-AA40-7F709DF9CAA4

Q29614803-4C6A18F1-A6E0-4ABD-BB27-9E2442F8D96A

P304

Q29614803-1C050567-62CB-49A8-8C50-A92622F2908F

P31

Q29614803-EEB6EBE9-DA22-457E-9540-9355DC27229B

P3181

Q29614803-3743A2DB-EB5A-4495-90A3-DFEC9EC398C8

P356

Q29614803-A8BA1152-143B-47B7-ADDE-D5CA6DC12AA3

P407

Q29614803-9FEC6C20-8A17-4E0E-A185-4F2CC6BCA0B3

P433

Q29614803-BBF6EDB5-FC6A-4371-981C-A62E076949BB

P478

Q29614803-611DB0B8-53FC-42DA-91E9-09348C3BFCA0

P577

Q29614803-D48D1229-0ED3-488D-A22B-4854D88EDFC5

P698

Q29614803-3D329E86-27C5-4D13-B33A-75B4632D12B5

P932

Q29614803-9D730330-B736-4B1A-9C24-5DD7BFCB5742

P3181

P356

JCO.2009.23.4799

P1433

Journal of Clinical Oncology

P1476

Final version of 2009 AJCC melanoma staging and classification

@en

P2093

Atkins MB

http://www.w3.org/2001/XMLSchema#string

Balch CM

http://www.w3.org/2001/XMLSchema#string

Buzaid AC

http://www.w3.org/2001/XMLSchema#string

Byrd DR

http://www.w3.org/2001/XMLSchema#string

Cochran AJ

http://www.w3.org/2001/XMLSchema#string

Coit DG

http://www.w3.org/2001/XMLSchema#string

Ding S

http://www.w3.org/2001/XMLSchema#string

Eggermont AM

http://www.w3.org/2001/XMLSchema#string

Flaherty KT

http://www.w3.org/2001/XMLSchema#string

Gershenwald JE

http://www.w3.org/2001/XMLSchema#string

P2860

Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis.

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.

Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients.

Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system.

Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas.

Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival.

Sentinel lymph node mapping for thick (>or=4-mm) melanoma: should we be doing it?

Immunohistochemical characteristics of melanoma.

A single-institution validation of the AJCC staging system for stage IV melanoma.

P304

6199-206

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

610409

http://www.w3.org/2001/XMLSchema#string

P356

10.1200/JCO.2009.23.4799

http://www.w3.org/2001/XMLSchema#string

P407

P433

36

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2009-12-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19917835

http://www.w3.org/2001/XMLSchema#string

P932

2793035

http://www.w3.org/2001/XMLSchema#string